From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative
- Resource Type
- Correspondence
- Source
- In
The Lancet Gastroenterology & Hepatology February 2021 6(2):88-89 - Subject
Analysis and Interpretation Correspondence - Language
- ISSN
- 2468-1253